CD163 and cancer: Although our image analysis found the preserved efficacy of CD163 immune abundance and use of morphologic variation to stratify novel enhancing lesions, the inability to stratify whether cancer cells present in tissue are proliferating prevent a pathologist from confidently claiming a lesion as psPD.